Clinical trial · no report yet · Phase 3
NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- NCT07566156 ↗
- Recruiting
- Astellas Pharma Global Development, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 13 | |
| YouTube | 5 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Urothelial Cancer; Urinary Bladder Neoplasms
- Interventions
- Enfortumab vedotin; Conventional Radiotherapy; Hypofractionated Radiotherapy; Cisplatin; Fluorouracil; Mitomycin C; Gemcitabine; Pembrolizumab
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 390 (estimated)
- Primary outcomes
- Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Astellas Pharma Global Development, Inc. with Pfizer
- Start
- May 11, 2026
- Primary completion
- Mar 31, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07566156 · updated Oct 19, 2026